Tanya Chotibut - Publications
Affiliations: | Louisiana State University Shreveport, Shreveport, LA, United States |
Year | Citation | Score | |||
---|---|---|---|---|---|
2017 | Chotibut T, Meadows S, Kasanga EA, McInnis T, Cantu MA, Bishop C, Salvatore MF. Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28631864 DOI: 10.1002/Mds.27077 | 0.596 | |||
2014 | Chotibut T, Fields V, Salvatore MF. Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals. Molecular Pharmacology. 86: 675-85. PMID 25208966 DOI: 10.1124/Mol.114.093302 | 0.698 | |||
2014 | Chotibut T, Davis RW, Arnold JC, Frenchek Z, Gurwara S, Bondada V, Geddes JW, Salvatore MF. Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model. Molecular Neurobiology. 49: 1282-92. PMID 24297323 DOI: 10.1007/S12035-013-8598-0 | 0.697 | |||
2012 | Chotibut T, Apple DM, Jefferis R, Salvatore MF. Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake. Plos One. 7: e52322. PMID 23300642 DOI: 10.1371/Journal.Pone.0052322 | 0.675 | |||
2012 | Salvatore MF, Davis RW, Arnold JC, Chotibut T. Transient striatal GLT-1 blockade increases EAAC1 expression, glutamate reuptake, and decreases tyrosine hydroxylase phosphorylation at ser(19). Experimental Neurology. 234: 428-36. PMID 22285253 DOI: 10.1016/J.Expneurol.2012.01.012 | 0.69 | |||
Show low-probability matches. |